Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 29:11:209-210.
doi: 10.1016/j.jdin.2023.03.004. eCollection 2023 Jun.

Real-world drug survival of patients with hidradenitis suppurativa treated with adalimumab

Ryan C Saal  1 , Sarah Alnaif  1 , Joshua F Edwards  1 , Jennifer A Wintringham  1 , Robert J Smith  1
Affiliations

Real-world drug survival of patients with hidradenitis suppurativa treated with adalimumab

Ryan C Saal et al. JAAD Int. .
No abstract available

Keywords: adalimumab; biologic longevity; biologics; hidradenitis suppurativa; hidradenitis suppurativa management; real-world effectiveness.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Visual representation of the course of hidradenitis suppurativa treatment for biologic-naïve patients initiated on a biologic.
See this image and copyright information in PMC

References

    1. Savage K.T., Flood K.S., Porter M.L., Kimball A.B. TNF-α inhibitors in the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis. 2019;10 doi: 10.1177/2040622319851640. - DOI - PMC - PubMed
    1. Menter A., Tyring S.K., Gordon K., et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–115. doi: 10.1016/j.jaad.2007.09.010. - DOI - PubMed
    1. van de Putte L.B., Atkins C., Malaise M., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63(5):508–516. doi: 10.1136/ard.2003.013052. - DOI - PMC - PubMed
    1. Ring H.C., Maul J.T., Yao Y., et al. Drug survival of biologics in patients with hidradenitis suppurativa. JAMA Dermatol. 2022;158(2):184–188. doi: 10.1001/jamadermatol.2021.4805. - DOI - PMC - PubMed

LinkOut - more resources